Onesource Specialty Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
OneSource Specialty Pharma (formerly Stelis Biopharma) reported Q1 FY26 consolidated revenue from operations of ₹3,272.70 million, up about 12% year-on-year from ₹2,922.89 million. On a standalone basis, revenue grew a much stronger ~34% to ₹3,210.12 million (vs ₹2,400.26 million). Consolidated loss after tax narrowed sharply to ₹(1.86) million versus ₹(55.47) million loss in Q1 FY25, while standalone swung to a profit of ₹248.15 million from a ₹239.66 million loss a year ago. The company booked an exceptional loss of ₹28.70 million linked to legal costs for the legacy Sputnik vaccine (Prestige) litigation. The company also confirmed it has fully repaid its listed non-convertible debentures. Auditor Deloitte Haskins & Sells issued an unmodified (clean) limited review conclusion.
Narrowing losses and a turnaround to standalone profit are encouraging, but the consolidated bottom line is still marginally in the red and a large Prestige BioPharma claim of USD 136.32 million (~₹1,168 crore) pending at the Singapore Arbitration Centre remains a key overhang that investors should monitor closely.